However, given that randomised–controlled evidence have confirmed that all CGRP mAbs display similar efficacy in patients with and without medication overuse across the different migraine subtypes [31], we are confident that the lack of this subgroup analysis did not bias the final study outcome. This evidence concerns the gene CALCA and migraine disorder.